Hostname: page-component-cd9895bd7-8ctnn Total loading time: 0 Render date: 2024-12-23T09:35:25.823Z Has data issue: false hasContentIssue false
  • English
  • Français

Weight gain in antipsychotic-naive patients: a review and meta-analysis

Published online by Cambridge University Press:  06 August 2009

I. Tarricone ,
B. Ferrari Gozzi ,
A. Serretti ,
D. Grieco  and
D. Berardi
I. Tarricone*
Affiliation:
Institute of Psychiatry, Bologna University, Italy
B. Ferrari Gozzi
Affiliation:
Institute of Psychiatry, Bologna University, Italy
A. Serretti
Affiliation:
Institute of Psychiatry, Bologna University, Italy
D. Grieco
Affiliation:
Institute of Psychiatry, Bologna University, Italy
D. Berardi
Affiliation:
Institute of Psychiatry, Bologna University, Italy
*
*Address for correspondence: Dr I. Tarricone, Institute of Psychiatry, Bologna University, Viale Pepoli 5, 40123 Bologna, Italy. (Email: [email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Weight gain is a long-recognized side-effect of antipsychotic (AP) drugs and a major health concern in the treatment of psychosis. The strength of the causal relationship between AP drug exposure and weight gain can only be gauged by a drugs trial conducted on AP-naive patients.

Method

We conducted a review of the literature regarding the amount of weight gain induced by APs in AP-naive patients and carried out a meta-analysis of mean weight gains.

Results

We found 11 primary studies reporting the effects of APs on body weight or body mass index (BMI) in AP-naive patients. The mean body weight and BMI gains in AP-naive patients were highly significant from the first weeks of treatment. When we limited the analysis to studies conducted on patients hospitalized and without any adjunctive treatment potentially affecting weight, the resultant sample showed less heterogeneity and confirmed the final picture of weight gain at around 3.8 kg and 1.2 points BMI.

Conclusions

Weight gain associated with AP therapy in AP-naive patients occurs rapidly in the first few weeks and continues during the following months. Clinicians should be aware of the high probability of causing weight gain in AP-naive patients and should strictly monitor such patients.

Keywords

Antipsychotic agentsantipsychotic-naiveBMI gainfirst-episode psychosisweight gain
Type
Review Article
Information
Psychological Medicine , Volume 40 , Issue 2 , February 2010 , pp. 187 - 200
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Addington, J, Mansley, C, Addington, D (2003). Weight gain in first-episode psychosis. Canadian Journal of Psychiatry 48, 272–276.Google Scholar
Allison, DB, Casey, DE (2001). Antipsychotic-induced weight gain: a review of the literature. Journal of Clinical Psychiatry 62, 22–31.Google ScholarPubMed
Allison, DB, Mentore, JL, Heo, M, Chandler, LP, Cappelleri, JC, Infante, MC, Weiden, PJ (1999). Antipsychotic-induced weight gain; a comprehensive research synthesis. American Journal of Psychiatry 156, 1686–1696.Google Scholar
Alvarez-Jiménez, M, González-Blanch, C, Crespo-Facorro, B, Hetrick, S, Rodríguez-Sánchez, JM, Pérez-Iglesias, R, Vázquez-Barquero, JL (2008). Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs 22, 547–562.CrossRefGoogle ScholarPubMed
Alvarez-Jimenez, M, Gonzalez-Blanch, C, Vazquez-Barquero, JL, Perez-Iglesias, R, Martinez-Garcia, O, Perez-Pardal, T, Ramirez-Bonilla, ML, Crespo-Facorro, B (2006). Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first episode psychosis patients: a randomized controlled trial. Journal of Clinical Psychiatry 67, 1253–1260.Google Scholar
American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Obesity Research 12, 362–368.CrossRefGoogle Scholar
Arranz, B, San, L, Duenas, RM, Centeno, M, Ramirez, N, Salavert, J, Del Moral, E (2007). Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients. Human Psychopharmacology 22, 11–15.CrossRefGoogle ScholarPubMed
Basile, VS, Masellis, M, McIntyre, RS, Meltzer, HY, Lieberman, JA, Kennedy, JL (2001). Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. Journal of Clinical Psychiatry 62, 45–66.Google ScholarPubMed
Basson, BR, Kinon, BJ, Taylor, CC, Szymanski, KA, Gilmore, JA, Tollefson, GD (2001). Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol or risperidone. Journal of Clinical Psychiatry 62, 231–238.CrossRefGoogle ScholarPubMed
Brecher, M, Leong, RW, Stening, G, Osterling-Koskinen, L, Jones, AM (2007). Quetiapine and long-term weight change: a comprehensive data review of patients with schizophrenia. Journal of Clinical Psychiatry 68, 597–603.CrossRefGoogle ScholarPubMed
Brown, S, Birtwistle, J, Roe, L, Thompson, C (1999). The unhealthy lifestyle of people with schizophrenia. Psychological Medicine 29, 697–701.Google Scholar
Caballero, E (2003). Obesity, diabetes, and the metabolic syndrome: new challenges in antipsychotic drug therapy. CNS Spectrums 11 (Suppl. 2), 19–22.Google Scholar
De Hert, MA, van Winkel, R, Van Eyck, D, Hanssens, L, Wampers, M, Scheen, A, Peuskens, J (2006). Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophrenia Research 83, 87–93.CrossRefGoogle ScholarPubMed
Egger, M, Smith, GD, Schneider, M, Minder, C (1997). Bias in meta-analysis detected by a simple, graphical test. British Medical Journal 315, 629–634.CrossRefGoogle ScholarPubMed
Ganguli, R, Brar, JS, Ayrton, Z (2001). Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone. Schizophrenia Research 49, 261–267.CrossRefGoogle ScholarPubMed
Gentile, S (2006). Long-term treatment with atypical antipsychotics and the risk of weight gain: a literature analysis. Drug Safety 29, 303–319.CrossRefGoogle ScholarPubMed
Haupt, DW (2006). Differential metabolic effects of antipsychotic treatments. European Neuropsychopharmacology 16 (Suppl. 3), S149–S155.CrossRefGoogle ScholarPubMed
Hedenmalm, K, Hagg, S, Stahl, M, Mortimer, O, Spigset, O (2002). Glucose intolerance with atypical antipsychotics. Drug Safety 25, 1107–1116.Google Scholar
Henderson, DC (2007). Weight gain with atypical antipsychotics: evidence and insights. Journal of Clinical Psychiatry 68 (Suppl. 12), 18–26.Google ScholarPubMed
Henderson, DC, Cagliero, E, Gray, C, Nasrallah, RA, Hayden, DL, Schoenfeld, DA, Goff, DC (2000). Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. American Journal of Psychiatry 157, 975–981.CrossRefGoogle ScholarPubMed
Kane, JM, Leucht, S, Carpenter, D, Docherty, JP; Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders (2003). The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. Journal Clinical Psychiatry 64, 5–19.Google ScholarPubMed
Kelly, DL, Conley, RR, Carpenter, WT (2005). First-episode schizophrenia: a focus on pharmacological treatment and safety considerations. Drugs 65, 1113–1138.CrossRefGoogle ScholarPubMed
Kinon, BJ, Basson, BR, Gilmore, JA, Tollefson, GD (2001). Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. Journal Clinical Psychiatry 62, 92–100.Google Scholar
Kurzthaler, I, Fleischhacker, WW (2001). The clinical implications of weight gain in schizophrenia. Journal of Clinical Psychiatry 62, 32–37.Google ScholarPubMed
Lee, E, Leung, CM, Wong, E (2004). Atypical antipsychotics and weight gain in Chinese patients: a comparison of olanzapine and risperidone. Journal of Clinical Psychiatry 65, 864–866.CrossRefGoogle ScholarPubMed
Lieberman, JA, Stroup, TS, McEvoy, JP, Swartz, MS, Rosenheck, RA, Perkins, DO, Keefe, RS, Davis, SM, Davis, CE, Lebowitz, BD, Severe, J, Hsiao, JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353, 1209–1223.CrossRefGoogle ScholarPubMed
Luty, J, Kelly, C, McCreadie, RG (2002). Smoking habits, body mass index and risk of heart disease: prospective 2½-year follow-up of first episode schizophrenic patients. Journal of Substance Use 7, 15–18.CrossRefGoogle Scholar
McEvoy, JP, Meyer, JM, Goff, DC, Nasrallah, HA, Davis, SM, Sullivan, L, Meltzer, HY, Hsiao, J, Stroup, ST, Lieberman, JA (2005). Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research 80, 19–32.CrossRefGoogle ScholarPubMed
McGavin, JK, Goa, KL (2002). Aripiprazole. CNS Drugs 16, 779–786.Google Scholar
McIntyre, RS, Trakas, K, Lin, D, Balshaw, R, Hwang, P, Robinson, K, Eggleston, A (2003). Risk of weight gain associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia. Canadian Journal of Psychiatry 48, 689–694.CrossRefGoogle ScholarPubMed
Meyer, JM (2002). A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. Journal of Clinical Psychiatry 63, 425–432.CrossRefGoogle ScholarPubMed
Munafò, MR, Flint, J (2004). Meta-analysis of genetic association studies. Trends in Genetics 20, 439–444.CrossRefGoogle ScholarPubMed
Perez-Iglesias, R, Crespo-Facorro, B, Amado, JA, Garcia-Unzueta, MT, Ramirez-Bonilla, ML, Gonzalez-Blanch, C, Martinez-Garcia, O, Vazquez-Barquero, JL (2007). A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. Journal of Clinical Psychiatry 68, 1733–1740.Google Scholar
Perez-Iglesias, R, Crespo-Facorro, B, Martinez-Garcia, O, Ramirez-Bonilla, ML, Alvarez-Jimenez, M, Pelayo-Teran, J, Garcia-Unzueta, MT, Amado, JA, Vazquez-Barquero, JL (2008 a). Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naive population. Schizophrenia Research 99, 13–22.CrossRefGoogle Scholar
Perez-Iglesias, R, Vazquez-Barquero, JL, Amado, JA, Berja, A, Garcia-Unzueta, MT, Pelayo-Terán, JM, Carrasco-Marín, E, Mata, I, Crespo-Facorro, B (2008 b). Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. Journal of Clinical Psychopharmacology 28, 289–295.CrossRefGoogle ScholarPubMed
Perkins, DO (1999). Adherence to antipsychotic medications. Journal of Clinical Psychiatry 60 (Suppl. 21), 25–30.Google ScholarPubMed
Perkins, DO (2002). Predictors of noncompliance in patients with schizophrenia. Journal of Clinical Psychiatry 63, 1121–1128.Google Scholar
RevMan, (2003). Review Manager (RevMan) (computer program). Version 4.2 for Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2003 (http://www.cochrane-net.org/download/revman/revman42.exe).Google Scholar
Reynolds, GP, Zhang, ZJ, Zhang, XB (2002). Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 359, 2086–2087.Google Scholar
Reynolds, GP, Zhang, ZJ, Zhang, XB (2003). Polymorphism of the promoter region of the serotonin 5-HT2C receptor gene and clozapine-induced weight gain. American Journal of Psychiatry 160, 677–679.Google Scholar
Robinson, DG, Woerner, MG, Delman, HM, Kane, JM (2005). Pharmacological treatments for first-episode schizophrenia. Schizophrenia Bulletin 31, 705–722.Google Scholar
Ryan, MC, Flanagan, S, Kinsella, U, Keeling, F, Thakore, JH (2004). The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sciences 74, 1999–2008.CrossRefGoogle ScholarPubMed
Saddichha, S, Ameen, S, Akhtar, S (2008 a). Predictors of antipsychotic-induced weight gain in first episode psychosis. Journal of Clinical Psychopharmacology 28, 27–31.CrossRefGoogle ScholarPubMed
Saddichha, S, Manjunatha, N, Ameen, S, Akhtar, S (2007 a). Effects of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study. Journal of Clinical Psychiatry 68, 1793–1798.Google ScholarPubMed
Saddichha, S, Manjunatha, N, Ameen, S, Akhtar, S (2008 b). Diabetes and schizophrenia – effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia. Acta Psychiatrica Scandinavica 117, 342–347.Google Scholar
Saddichha, S, Shaul, A, Sayeed, A (2007 b). Incidence of new onset metabolic syndrome with atypical antipsychotics in first episode of schizophrenia: a six-week prospective study in Indian female patients. Schizophrenia Research 95, 247.CrossRefGoogle ScholarPubMed
Scheen, AJ, De Hert, MA (2007). Abnormal glucose metabolism in patients treated with antipsychotics. Diabetes and Metabolism 33, 169–175.Google Scholar
Tarricone, I, Serretti, A, Ferrari Gozzi, B, Mandelli, L, Grieco, D, Mellini, L, Bigini, S, Berti, B, Berardi, D (2008). Metabolic side effects of second generation antipsychotic agents in antipsychotic-naive patients: one-month prospective evaluation. Psychiatry Research 157, 269–271.Google Scholar
Taylor, DM, McAskill, R (2000). Atypical antipsychotics and weight gain – a systematic review. Acta Psychiatrica Scandinavica 101, 16–32.Google Scholar
Templeman, LA, Reynolds, GP, Arranz, B, San, L (2005). Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenetics and Genomics 15, 195–200.Google Scholar
Wetterling, T, Mussigbrodt, H (1999). Weight gain: side effect of atypical neuroleptics? Journal of Clinical Psychopharmacology 14, 316–321.Google Scholar
Wirshing, DA (2001). Adverse effects of atypical antipsychotics. Journal of Clinical Psychiatry 62, 7–10.Google ScholarPubMed
Wirshing, DA (2004). Schizophrenia and obesity: impact of antipsychotic medications. Journal of Clinical Psychiatry 65 (Suppl. 18), 13–26.Google ScholarPubMed
Wirshing, DA, Pierre, JM, Wirshing, WC (2002). Sleep apnea associated with antipsychotic-induced obesity. Journal of Clinical Psychiatry 63, 369–370.Google Scholar
Wirshing, DA, Wirshing, WC, Kysar, L, Berisford, MA, Goldstein, D, Pashdag, J, Mintz, J, Marder, SR (1999). Novel antipsychotics: comparison of weight gain liabilities. Journal of Clinical Psychiatry 60, 358–363.CrossRefGoogle ScholarPubMed
Wu, RR, Zhao, JP, Liu, ZN, Zhai, JG, Guo, XF, Guo, WB, Tang, JS (2006). Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology 186, 572–578.CrossRefGoogle ScholarPubMed
Wu, RR, Zhao, JP, Zhai, JG, Guo, XF, Guo, WB (2007). Sex difference in effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Journal of Clinical Psychopharmacology 27, 374–379.CrossRefGoogle ScholarPubMed
Yap, HL, Mahendran, R, Lim, D, Liow, PH, Lee, A, Phang, S, Tiong, A (2001). Risperidone in the treatment of first episode psychosis. Singapore Medical Journal 42, 170–173.Google ScholarPubMed
Zhang, ZJ, Yao, ZJ, Liu, W, Fang, Q, Reynolds, GP (2004). Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. British Journal of Psychiatry 184, 58–62.Google Scholar
Zhang, ZJ, Yao, ZJ, Zhang, XB, Chen, JF, Sun, J, Yao, H, Hou, G, Zhang, XB (2003). No association of antipsychotic agent-induced weight gain with a DA receptor gene polymorphism and therapeutic response. Acta Pharmacologica Sinica 24, 235–240.Google Scholar